65017-93-8

Basic information

• Product Name: 2H-Naphtho[1,2-b]pyran-5,6-dione, 3-bromo-3,4-dihydro-4-hydroxy-2,2-dimethyl-
• CAS NO: 65017-93-8
• Molecular Formula: C15H13BrO4
• Molecular Weight: 337.17
• Mol File: 65017-93-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2H-Naphtho[1,2-b]pyran-5,6-dione, 3-bromo-3,4-dihydro-4-hydroxy-2,2-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Naphtho[1,2-b]pyran-5,6-dione, 3-bromo-3,4-dihydro-4-hydroxy-2,2-dimethyl-(65017-93-8)
• EPA Substance Registry System: 2H-Naphtho[1,2-b]pyran-5,6-dione, 3-bromo-3,4-dihydro-4-hydroxy-2,2-dimethyl-(65017-93-8)

Safety Data

• Hazardous Substances Data: 65017-93-8(Hazardous Substances Data)

Upstream product

• 84-79-7 Lapachol 
• 4707-32-8 2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione 

Relevant articles and documents

Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line

Catalyst/HypoGen pharmacophore modeling approach and three-dimensional quantitative structure-activity relationship (3D-QSAR)/comparative molecular similarity indices analysis (CoMSIA) methods have been successfully applied to explain the cytotoxic activity of a set of 51 natural and synthesized naphthoquinone derivatives tested in human promyelocytic leukemia HL-60 cell line. The computational models have facilitated the identification of structural elements of the ligands that are key for antitumoral properties. The four most salient features of the highly active β-cycled-pyran-1,2-naphthoquinones [0.1 μM 50 0.6 μM] are the hydrogen-bond interactions of the carbonyl groups at C-1 (HBA1) and C-2 (HBA2), the hydrogen-bond interaction of the oxygen atom of the pyran ring (HBA3), and the interaction of methyl groups (HYD) at the pyran ring with a hydrophobic area at the receptor. The moderately active 1,4-naphthoquinone derivatives accurately fulfill only three of these features. The results of our study provide a valuable tool in designing new and more potent cytotoxic analogues.